ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

BCAB Company Profile and Key Details

NASDAQ : BCAB

BioAtla, Inc.

$0.29

0.0099+3.53%

At Close 4:00 PM

56.94

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

BCAB Stock Price Chart

Stock Price Today

BioAtla, Inc. (BCAB) stock surged +3.53%, trading at $0.29 on NASDAQ, up from the previous close of $0.28. The stock opened at $0.28, fluctuating between $0.27 and $0.30 in the recent session.

Stock Snapshot

0.2802

Prev. Close

0.28

Open

16.94M

Market Cap

58.4M

Number of Shares

0.2652

Day Low

0.3

Day High

-0.2

P/E Ratio

77.69%

Free Float in %

-1.44

EPS (TTM)

1.47

Book Value

-2.17

Cash Flow per Share

617.42K

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 07, 2025	0.28	0.30	0.26	0.29	617.42K
Apr 04, 2025	0.29	0.32	0.26	0.28	891.86K
Apr 03, 2025	0.33	0.34	0.30	0.30	780.06K
Apr 02, 2025	0.36	0.36	0.34	0.34	397.88K
Apr 01, 2025	0.34	0.36	0.33	0.35	501.74K
Mar 31, 2025	0.37	0.37	0.32	0.35	696.94K
Mar 28, 2025	0.34	0.38	0.28	0.37	1.42M
Mar 27, 2025	0.38	0.40	0.36	0.39	1.21M
Mar 26, 2025	0.38	0.38	0.37	0.37	529.81K
Mar 25, 2025	0.38	0.39	0.37	0.37	343.74K
Mar 24, 2025	0.35	0.40	0.35	0.37	779.82K
Mar 21, 2025	0.36	0.37	0.35	0.35	306.54K
Mar 20, 2025	0.37	0.38	0.36	0.36	140.57K
Mar 19, 2025	0.35	0.38	0.35	0.36	393.02K
Mar 18, 2025	0.38	0.39	0.35	0.36	483.95K
Mar 17, 2025	0.35	0.37	0.32	0.36	439.75K
Mar 14, 2025	0.34	0.35	0.33	0.34	488.35K
Mar 13, 2025	0.35	0.35	0.31	0.32	405.34K
Mar 12, 2025	0.31	0.34	0.30	0.34	470.59K
Mar 11, 2025	0.32	0.33	0.30	0.31	383K

Contact Details

San Diego, CA 92121

United States

Website: https://www.bioatla.comContact: 858 558 0708

About Company

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Frequently Asked Questions

What is the current BioAtla, Inc. (BCAB) stock price?

BioAtla, Inc. (NASDAQ: BCAB) stock price is $0.29 in the last trading session. During the trading session, BCAB stock reached the peak price of $0.30 while $0.27 was the lowest point it dropped to. The percentage change in BCAB stock occurred in the recent session was 3.53% while the dollar amount for the price change in BCAB stock was $0.01.

BCAB's industry and sector of operation?

The NASDAQ listed BCAB is part of Biotechnology industry that operates in the broader Healthcare sector. BioAtla, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BCAB?

Dr. Eric L. Sievers M.D.
Chief Medical Officer
Ms. Susie Melody
Senior Vice President of HR
Mr. Philippe Martin
Chief Clinical Devel. & Operations
Ms. Monica Sullivan
Senior Vice President of Intellectual Property & Contracts
Dr. Jay M. Short Ph.D.
Co-Founder, Chief Executive Officer & Chairman
Dr. Cathy Chang Ph.D.
Senior Vice President of R&D
Lisa M. Pelton
Accounting Mang.
Dr. Gerhard Frey Ph.D.
Senior Vice President of Technology Devel.
Ms. Sheri Lydick
Senior Vice President of Commercial Strategy
Mr. Richard A. Waldron
Senior Vice President & Chief Financial Officer
Mr. Christian Vasquez
Senior Vice President of Fin. & Sec.
Mr. Christian J. Vasquez
Senior Vice President of Fin., Corporation Controller & Sec.
Mr. Scott Andrew Smith
Chief Executive Officer & Director

How BCAB did perform over past 52-week?

BCAB's closing price is 20.88% higher than its 52-week low of $0.24 where as its distance from 52-week high of $3.97 is -92.69%.

How many employees does BCAB have?

Number of BCAB employees currently stands at 65.

Link for BCAB official website?

Official Website of BCAB is: https://www.bioatla.com

How do I contact BCAB?

BCAB could be contacted at phone 858 558 0708 and can also be accessed through its website. BCAB operates from 11085 Torreyana Road, San Diego, CA 92121, United States.

How many shares of BCAB are traded daily?

BCAB stock volume for the day was 617.42K shares. The average number of BCAB shares traded daily for last 3 months was 815.69K.

What is the market cap of BCAB currently?

The market value of BCAB currently stands at $16.94M with its latest stock price at $0.29 and 58.4M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	65
Beta	1.18
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology